LL-37

Controlled topical trial · no overall healing benefit.



Guide prepared November 13, 2026 · profile review dates retained

KEEP IN MIND Evidence applies to the studied formulation, route, population and outcome—not every product sharing a name.

01 What is it?

LL-37 is a human immune-defense peptide studied for antimicrobial activity and wound repair. Controlled research includes topical treatment of venous leg ulcers, but that experience does not establish benefit for systemic injections or general immune enhancement. [1]

02 Potential benefits

Part of human innate immune defense. Studied for antimicrobial, immune, and wound-related effects. [1]

03 Evidence & its limits

The 2021 trial found no significant healing advantage over placebo across the entire study population. Exploratory subgroup findings require confirmation. Both the route and setting matter: topical ulcer treatment with compression is not evidence for injected LL-37 or broad infection treatment. [1]

04 Risks & unknowns

Direct therapeutic use remains experimental. It can also promote inflammation or tissue injury in some contexts. [1]

05 Status & scope

The cited topical wound trial did not establish an overall healing benefit. It does not validate systemic injections or unrelated immune-health claims. [1]

06 The question to ask

Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.

SOURCES / Tap a reference to open

[1] Full evidence record, references and review dates
[2] Exploratory randomized topical LL-37 trial, 2014
[3] HEAL LL-37 phase IIb randomized trial, 2021

Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.